HomeCompareTIKK vs PFE

TIKK vs PFE: Dividend Comparison 2026

TIKK yields 142.86% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TIKK wins by $19.50M in total portfolio value
10 years
TIKK
TIKK
● Live price
142.86%
Share price
$1.40
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.55M
Annual income
$8,225,014.26
Full TIKK calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — TIKK vs PFE

📍 TIKK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTIKKPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TIKK + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TIKK pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TIKK
Annual income on $10K today (after 15% tax)
$12,142.86/yr
After 10yr DRIP, annual income (after tax)
$6,991,262.12/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, TIKK beats the other by $6,968,942.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TIKK + PFE for your $10,000?

TIKK: 50%PFE: 50%
100% PFE50/50100% TIKK
Portfolio after 10yr
$9.80M
Annual income
$4,125,636.49/yr
Blended yield
42.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

TIKK
No analyst data
Altman Z
-1056684.7
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TIKK buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTIKKPFE
Forward yield142.86%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$19.55M$49.6K
Annual income after 10y$8,225,014.26$26,258.71
Total dividends collected$18.03M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TIKK vs PFE ($10,000, DRIP)

YearTIKK PortfolioTIKK Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$24,986$14,285.71$9,153$693.39+$15.8KTIKK
2$60,093$33,358.76$8,593$849.25+$51.5KTIKK
3$139,283$74,982.82$8,336$1,066.78+$130.9KTIKK
4$311,456$162,423.26$8,437$1,384.80+$303.0KTIKK
5$672,698$339,440.31$9,013$1,875.40+$663.7KTIKK
6$1,404,965$685,177.81$10,306$2,680.72+$1.39MTIKK
7$2,840,723$1,337,410.52$12,820$4,101.38+$2.83MTIKK
8$5,566,801$2,527,227.75$17,673$6,826.70+$5.55MTIKK
9$10,584,947$4,628,469.98$27,543$12,591.86+$10.56MTIKK
10$19,550,908$8,225,014.26$49,560$26,258.71+$19.50MTIKK

TIKK vs PFE: Complete Analysis 2026

TIKKStock

Tel-Instrument Electronics Corp. designs, manufactures, and sells avionics test and measurement instruments for the commercial air transport, general aviation, and government/military aerospace and defense markets in the United States and internationally. It operates through two segments, Avionics Government and Avionics Commercial. The company provides instruments to test, measure, calibrate, and repair a range of airborne navigation and communication equipment. Its products also include TS-4530A and T-4530i, an identification friend or foe test sets; and T-47/M5, a dual crypto test set. The company also offers AN/USM-708 and AN/USM-719 communications/navigation radio frequency avionics flight line testers; SDR-OMNI, an avionics test set; and Lockheed Martin MADL test set, a secure communications radio for the F-35. It serves customers directly or through distributors. The company was incorporated in 1947 and is headquartered in East Rutherford, New Jersey.

Full TIKK Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this TIKK vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TIKK vs SCHDTIKK vs JEPITIKK vs OTIKK vs KOTIKK vs MAINTIKK vs JNJTIKK vs MRKTIKK vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.